H. Roché

发表

Vascular Permeability Factor: A Tumor-derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration

Roche ResearchCenter, H. Roché, 1990 .

STATISTICAL ANALYSIS OF PROTEIN FOLDING KINETICS

M. Karplus, S. So, A. U.S., 2002 .

Translational research : current status , challenges and future strategies

H. Roché, 2011 .

LIVER, PANCREAS, AND BILIARY TRACT Tumor Necrosis Factor Receptors in Patients With Chronic Hepatitis B Virus Infection

B. Portmann, Roger Williams, G. Marinos, 1995 .

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

G. Houin, P. Canal, C. Chevreau, 1995, Journal of the National Cancer Institute.

Inhibition ofEstrogen-Responsive GeneActivation bythe Retinoid X Receptor ,B: Evidence forMultiple Inhibitory Pathways

S. Hirschfeld, E. Martinez, H. Roché, 1993 .

Chronopharmacokinetics of doxorubicin in patients with breast cancer

G. Houin, P. Canal, C. Chevreau, 2004, European Journal of Clinical Pharmacology.

Production ofHumanc-myc Protein inInsect Cells Infected witha Baculovirus Expression Vector

H. Roché, 1985 .

Cloning and sequencing* of the leu C and npr M genes and a putative spo IV gene from Bacillus megaterium DSM319

H. Roché, 1994 .

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.

G. Milano, P. Canal, E. Chatelut, 1993, Journal of the National Cancer Institute.

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

G. Milano, J. Robert, P. Canal, 1994, British Journal of Cancer.

Characterization and chemosensitivity of a human epithelioid sarcoma cell line (SARCCR 2)

G. Laurent, N. Dastugue, P. Canal, 1993, International journal of cancer.

Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing Krebs II ascitic tumors.

P. Canal, R. Bugat, H. Roché, 1986, European journal of cancer & clinical oncology.

Mutational andKinetic Analyses oftheGTPase-Activating Protein (GAP)-p2l Interaction: TheC-Terminal DomainofGAP IsNot Sufficient forFullActivity

J. John, H. Roché, R. Clark, 1992 .

analysis of surviving virus shows added selective pressure of combination

I. Maclachlan, D. Chin, A. Dallas, 2014 .

Inhaled Dose Translation from Rodent to Human: A Retrospective Analysis of Mometasone Furoate

C. Stevenson, J. Phillips, H. Roché, 2012 .

Trimethoprim, Alone and in Combination

H. Roché, R. Then, P. Angehrn, 1973 .

[Immunotherapy of multiple recurring warts. II. Reassessment of the use of squaric acid dibutylester (SADBE) (author's transl)].

H. Roché, A. Claudy, 1981, Annales de dermatologie et de venereologie.

polymerase inhibitor, in adult dengue patients

Than Ha Quyen, A. Wilm, N. Nagarajan, 2012 .

Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4.

B. Monsarrat, P. Canal, E. Chatelut, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.

G. Laurent, P. Canal, C. Chevreau, 1991, European journal of cancer.

A Simple Simultaneous Colorimetric Determination of Primary and Secondary Amines with Fluorescamine

H. Roché, V. Toome, K. Manhart, 1975 .

LOYALTY REBATES AFTER INTEL : TIME FOR THE EUROPEAN COURT OF JUSTICE TO

H. Roché, 2015 .

Sebum-suppressing of the nonpolar arotinoid Ro 15-0778 in rodents

H. Roché, A. Boris, J. Hurley, 1988 .

Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.

G. Houin, P. Canal, C. Chevreau, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

PHARMACOKINETICS OF HIGH‐DOSE IV ALIZAPRIDE IN PREVENTION OF CISPLATIN‐INDUCED EMESIS

P. Canal, R. Bugat, H. Roché, 1987, Fundamental & clinical pharmacology.

CPT: Pharmacometrics & Systems Pharmacology

Ghent, M. Jamei, D. Ashcroft, 2013, CPT: pharmacometrics & systems pharmacology.

Isotretinoin (Accutane) as a Teratogen [1]

H. Roché, 2017 .

In vivo measurement of transepidermal water loss

H. Roché, B. Idson, 1978 .

Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis

B. Strandvik, M. Hodson, J. Navarro, 2003, Pediatric pulmonology.

Management of cancer patients receiving interferon alfa‐2a

H. Roché, L. Gauci, Co. Ltd, 1987, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.

G. Houin, P. Canal, E. Chatelut, 1991, Journal of pharmaceutical sciences.

European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of major disease manifestations between patients with different classes of mutations

B. Strandvik, M. Hodson, J. Navarro, 2001, Pediatric pulmonology.

Non-linearity of colony formation by human tumour cells from biopsy samples.

M. Aapro, H. Roché, J. Eliason, 1985, British Journal of Cancer.

Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal.

P. Canal, J. Dueymes, J. Pourrat, 1989, Nephron.

Safety, Tolerability and Pharmacokinetics of the N‐Methyl‐d‐Aspartate Antagonist Ro‐01–6794/706 in Patients with Acute Ischemic Stroke a b

H. Roché, 1995 .

Interleukin-1 2-Induced Adhesion Molecule Expression inMurine Liver

H. Roché, 1998 .

Plasmodium falciparum‐specific human T cell clones: recognition of different parasite antigens

J. Richard, F. Sinigaglia, H. Roché, 1987, European journal of immunology.

In‐vivo effects of anti‐inflammatory and other drugs on granulocyte emigration in the rabbit skin collection chamber

J. Borel, H. Roché, C. Feurer, 1978, The Journal of pathology.